---
title: "Barclays maintains CoreWeave at Equal-Weight, lowers price target to $85 from $105"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305359425.md"
description: "Barclays maintains a rating of Equal-Weight for CoreWeave but lowers its price target from $105 to $85, representing a 19% decrease. This new target implies a 39.9% upside potential from the November 11 closing price of $60.77. The update is part of recent analyst activity, with other firms like Macquarie and Citigroup maintaining their ratings and targets over the past month."
datetime: "2026-11-12T18:32:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305359425.md)
  - [en](https://longbridge.com/en/news/305359425.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305359425.md)
generator: "portal-rs"
---

# Barclays maintains CoreWeave at Equal-Weight, lowers price target to $85 from $105

Barclays maintained CoreWeave at Equal-Weight and lowered its price target to $85 from $105, a 19.0% decrease.

The price target implies an upside of 39.9% from the Nov 11 close of $60.77.

**Recent analyst actions on CoreWeave**

| Date   | Firm               | Action    | Rating     | Price target |
| ------ | ------------------ | --------- | ---------- | ------------ |
| Nov 12 | Macquarie          | Maintains | Outperform | $120         |
| Nov 12 | Argus Research     | Maintains | Buy        | $100         |
| Nov 11 | Citigroup          | Maintains | Buy        | $149         |
| Nov 11 | DA Davidson        | Maintains | Neutral    | $45          |
| Nov 11 | Evercore ISI Group | Maintains | Outperform | $100         |

Across the five most recent analyst notes published on CoreWeave over the past 30 days, price targets range from $45 to $149.

Explore more price target data and ratings for CoreWeave on the , and track all previous and future analyst recommendations in the dedicated News Flow.

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [CRWV.US](https://longbridge.com/en/quote/CRWV.US.md)
- [CORD.US](https://longbridge.com/en/quote/CORD.US.md)
- [CRWG.US](https://longbridge.com/en/quote/CRWG.US.md)
- [CRWU.US](https://longbridge.com/en/quote/CRWU.US.md)
- [CRWX.US](https://longbridge.com/en/quote/CRWX.US.md)
- [CWVX.US](https://longbridge.com/en/quote/CWVX.US.md)
- [CWY.US](https://longbridge.com/en/quote/CWY.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)

## Related News & Research

- [CoreWeave’s 168% Q3 Revenue Growth Splits Analysts: One Sees It ‘Continuing to Destroy Value’](https://longbridge.com/en/news/305198021.md)
- [Needham maintains CoreWeave at Hold](https://longbridge.com/en/news/305169004.md)
- [CoreWeave Seeks $4B Loan as CEO Addresses Debt Fears; Analysts See 78% Upside](https://longbridge.com/en/news/305255123.md)
- [CoreWeave finds a workaround to capital constraints—for now](https://longbridge.com/en/news/305153630.md)
- [CoreWeave Q3 Earnings Preview: Revenue Expected to Grow 159%, Debt and Financing Costs in Focus, Wall Street's Top Price Target at $278](https://longbridge.com/en/news/304812583.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**